From: Xenon in the treatment of panic disorder: an open label study
Group | |||
---|---|---|---|
“Pure” PD (n = 42) | “Comorbid” PD (n = 39) | Total (n = 81) | |
Age, years | |||
Mean | 36.1 | 34.3 | 35.2 |
Standard deviation | 12.90 | 12.20 | 12.52 |
Median | 32.0 | 33.0 | 33.0 |
Minimum | 19 | 18 | 18 |
Maximum | 69 | 68 | 69 |
Sex | |||
Male, n (%) | 22 (52.4%) | 10 (25.6%) | 32 (39.5%) |
Female, n (%) | 20 (47.6%) | 29 (74.4%) | 49 (60.5%) |
Employment | |||
No, n (%) | 19 (45.2%) | 18 (46.2%) | 37 (45.7%) |
Yes, n (%) | 23 (54.8%) | 21 (53.8%) | 44 (54.3%) |
Disease duration, months | |||
Mean | 8.9 | 16.9 | 12.8 |
Standard deviation | 5.28 | 7.54 | 7.60 |
Median | 6.0 | 18.0 | 12.0 |
Minimum | 3 | 3 | 3 |
Maximum | 18 | 24 | 24 |
Marriage status | |||
No, n (%) | 16 (38.1%) | 21 (53.8%) | 37 (45.7%) |
Yes, n (%) | 26 (61.9%) | 18 (46.2%) | 44 (54.3%) |
Children | |||
No, n (%) | 17 (40.5%) | 21 (53.8%) | 38 (46.9%) |
Yes, n (%) | 25 (59.5%) | 18 (46.2%) | 43 (53.1%) |